NCT02521844: A Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active, unstable, or untreated central nervous system (brain or leptomeningeal) metastases- see trial for details; Patients with bone metastases

Comments are closed.

Up ↑